339316-68-6

Upstream product

• 1078691-95-8 (+)-D-glucosamine hydrochloride 
• 172490-46-9 2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-D-glucopyranose 
• 100-51-6 benzyl alcohol 

Downstream Products

• 1372616-70-0 benzyl 2-deoxy-4,6-O-benzylidene-3-O-(2,2,2-trichloro-ethoxycarbonyl)-2-(2,2,2-trichloro-ethoxycarbonylamino)-α-D-glucopyranoside 
• 1372616-71-1 1,6-di-O-benzyl-2-deoxy-3-O-(2,2,2-trichloro-ethoxycarbonyl)-2-(2,2,2-trichloro-ethoxy-carbonylamino)-α-D-glucopyranoside 
• 1372616-72-2 1,6-di-O-benzyl-4-O-[3,4,6-tri-O-acetyl-2-deoxy-2-(2,2,2-trichloro-ethoxycarbonylamino)-α-D-glucopyranosyl]-3-O-(2,2,2-trichloro-ethoxycarbonyl)-2-deoxy-2-(2,2,2-trichloro-ethoxy-carbonylamino)-α-D-glucopyranoside 
• 1372616-73-3 1,6-Di-O-benzyl-4-O-[3,4,6-tri-O-acetyl-2-acetamido-α-D-glucopyranosyl]-2-acetamido-α-D-glucopyranoside 
• 176019-96-8 benzyl 4,6-O-benzylidene-2-deoxy-2-(2,2,2-trichloro-ethoxycarbonylamino)-α-D-glucopyranoside 

Relevant academic research and scientific papers

SYNTHETIC INNATE IMMUNE RECEPTOR LIGANDS AND USES THEREOF

An adjuvant formulation includes a monophosphoryl Lipid A (MPLA) analogue, a Pam3CSK4 analogue, or a muramyldipeptide (MDP) analogue, or combinations thereof. The adjuvant may be formulated in soluble form or in a nanoparticle, such as polylactic glycolic acid nanoparticles. A vaccine formulation comprises the adjuvant formulation and an immunogen. Methods of vaccinating an animal include delivering the vaccine formulation to the animal.

SYNTHETIC DERIVATIVES OF MPL AND USES THEREOF

In one aspect, the present disclosure provides compounds of formulae (I) and (II). In another aspect, a compound of formula (I) or (II) is formulated into compositions with an antigen, optionally with a vesicle. In some embodiments, compositions are administered intramuscularly.